metformin has been researched along with Vascular Diseases in 22 studies
Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289)
metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.
Vascular Diseases: Pathological processes involving any of the BLOOD VESSELS in the cardiac or peripheral circulation. They include diseases of ARTERIES; VEINS; and rest of the vasculature system in the body.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Metformin has been used as an oral anti-hyperglycaemic drug since the late 1950s; however, following the release in 1998 of the findings of the 20-year United Kingdom Prospective Diabetes Study (UKPDS), metformin use rapidly increased and today is the first-choice anti-hyperglycaemic drug for patients with type 2 diabetes (T2D)." | 3.01 | Repurposing Metformin for Vascular Disease. ( Anderson, TJ; Ding, H; Hill, MA; Hollenberg, MD; Marei, I; Triggle, CR; Ye, K, 2023) |
| "Oral metformin 850mg bid was administered to PCOS patients." | 2.73 | Evaluation of endothelial function in women with polycystic ovary syndrome. ( Blumenfeld, Z; Damti, A; Lowenstein, L; Pillar, G; Shott, S, 2007) |
| "Metformin treatment significantly reduced carotid artery intima-media thickness (MD -0." | 2.66 | Vascular and metabolic effects of metformin added to insulin therapy in patients with type 1 diabetes: A systematic review and meta-analysis. ( Chen, CN; Chen, ZG; Lin, XP; Liu, YS; Peng, Y; Xu, LL, 2020) |
| "Metformin has unique, intrinsic actions specifically at the level of terminal arterioles, which are completely independent of its antidiabetic effect." | 2.48 | Microvascular diseases: is a new era coming? ( Rapin, JR; Wiernsperger, N, 2012) |
| "Metformin is an antihyperglycaemic drug with pleiotropic effects that result in cardiovascular improvement." | 1.40 | Metformin ameliorates ovariectomy-induced vascular dysfunction in non-diabetic Wistar rats. ( Bissoli, NS; Caliman, IF; de Abreu, GR; de Andrade, TU; de Figueiredo, SG; de Sousa, GJ; Lamas, AZ; Oliveira, PW; Santos de Medeiros, AR, 2014) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (18.18) | 18.7374 |
| 1990's | 2 (9.09) | 18.2507 |
| 2000's | 3 (13.64) | 29.6817 |
| 2010's | 7 (31.82) | 24.3611 |
| 2020's | 6 (27.27) | 2.80 |
| Authors | Studies |
|---|---|
| Triggle, CR | 2 |
| Marei, I | 1 |
| Ye, K | 1 |
| Ding, H | 2 |
| Anderson, TJ | 1 |
| Hollenberg, MD | 1 |
| Hill, MA | 1 |
| Chellian, J | 2 |
| Mak, KK | 2 |
| Chellappan, DK | 2 |
| Krishnappa, P | 2 |
| Pichika, MR | 2 |
| Mone, P | 1 |
| Lombardi, A | 1 |
| Kansakar, U | 1 |
| Varzideh, F | 1 |
| Jankauskas, SS | 1 |
| Pansini, A | 1 |
| Marzocco, S | 1 |
| De Gennaro, S | 1 |
| Famiglietti, M | 1 |
| Macina, G | 1 |
| Frullone, S | 1 |
| Santulli, G | 1 |
| Liu, YS | 1 |
| Chen, CN | 1 |
| Chen, ZG | 1 |
| Peng, Y | 1 |
| Lin, XP | 1 |
| Xu, LL | 1 |
| Ferrannini, G | 1 |
| Gerstein, H | 1 |
| Colhoun, HM | 1 |
| Dagenais, GR | 1 |
| Diaz, R | 1 |
| Dyal, L | 1 |
| Lakshmanan, M | 1 |
| Mellbin, L | 1 |
| Probstfield, J | 1 |
| Riddle, MC | 1 |
| Shaw, JE | 1 |
| Avezum, A | 1 |
| Basile, JN | 1 |
| Cushman, WC | 1 |
| Jansky, P | 1 |
| Keltai, M | 1 |
| Lanas, F | 1 |
| Leiter, LA | 1 |
| Lopez-Jaramillo, P | 1 |
| Pais, P | 1 |
| Pīrāgs, V | 1 |
| Pogosova, N | 1 |
| Raubenheimer, PJ | 1 |
| Sheu, WH | 2 |
| Rydén, L | 1 |
| Ionică, LN | 1 |
| Gaiță, L | 1 |
| Bînă, AM | 1 |
| Soșdean, R | 1 |
| Lighezan, R | 1 |
| Sima, A | 1 |
| Malița, D | 1 |
| Crețu, OM | 1 |
| Burlacu, O | 1 |
| Muntean, DM | 1 |
| Sturza, A | 1 |
| Oliveira, PW | 1 |
| de Sousa, GJ | 1 |
| Caliman, IF | 1 |
| Lamas, AZ | 1 |
| Santos de Medeiros, AR | 1 |
| de Andrade, TU | 1 |
| de Abreu, GR | 1 |
| de Figueiredo, SG | 1 |
| Bissoli, NS | 1 |
| Kinaan, M | 1 |
| Misra, A | 1 |
| Ke, CC | 1 |
| Lai, HC | 1 |
| Lin, CH | 1 |
| Hung, CJ | 1 |
| Chen, DY | 1 |
| Lui, PW | 1 |
| Heller, SR | 1 |
| Ewart, MA | 1 |
| Kennedy, S | 1 |
| Wiernsperger, N | 1 |
| Rapin, JR | 1 |
| Lowenstein, L | 1 |
| Damti, A | 1 |
| Pillar, G | 1 |
| Shott, S | 1 |
| Blumenfeld, Z | 1 |
| Holmwood, C | 1 |
| Philips, P | 1 |
| Verstraete, M | 1 |
| Montanari, G | 1 |
| Bondioli, A | 1 |
| Rizzato, G | 1 |
| Puttini, M | 1 |
| Tremoli, E | 1 |
| Mussoni, L | 1 |
| Mannucci, L | 1 |
| Pazzucconi, F | 1 |
| Sirtori, CR | 1 |
| Fearnley, GR | 2 |
| Chakrabarti, R | 2 |
| Hocking, ED | 1 |
| Evans, JF | 1 |
| Schneider, T | 1 |
| Lopis, S | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Emirates Heart Health Project: A Stepped-wedge Cluster Randomized-controlled Trial of a Family-based Health Coach Guided Dietary and Exercise Intervention for Reducing Weight and Cardiovascular Risk in Overweight and Obese Adult Nationals of the Unite[NCT04688684] | 80 participants (Anticipated) | Interventional | 2022-06-01 | Not yet recruiting | |||
| Diabetes Prevention Program Outcomes Study[NCT00038727] | Phase 3 | 2,779 participants (Actual) | Interventional | 2002-09-30 | Active, not recruiting | ||
| [NCT00004992] | Phase 3 | 3,234 participants (Actual) | Interventional | 1996-07-31 | Completed | ||
| Assessment of a Peripheral Endothelial Dysfunction in COPD (Chronic Obstructive Pulmonary Disease)[NCT02593357] | 137 participants (Actual) | Interventional | 2012-12-17 | Completed | |||
| Peripheral Endothelial Function in Asthmatic Patients[NCT02593344] | 113 participants (Actual) | Interventional | 2012-12-13 | Completed | |||
| A Randomized Trial of Metformin as Adjunct Therapy for Overweight Adolescents With Type 1 Diabetes[NCT01881828] | Phase 3 | 164 participants (Actual) | Interventional | 2013-09-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Primary outcome for years 2002-2008 defined according to American Diabetes Association criteria (fasting plasma glucose level >= 126 mg/dL [7.0 mmol/L] or 2-hour plasma glucose >= 200 mg/dL [11.1 mmol/L], after a 75 gram oral glucose tolerance test (OGTT), and confirmed with a repeat test). (NCT00038727)
Timeframe: Outcomes were assessed from 1996-2008 (approximately 12 years including 6 years of DPP).
| Intervention | diabetes incidence (cases per 100 person (Number) |
|---|---|
| 1 Original Lifestyle | 5.3 |
| 2 Original Metformin | 6.4 |
| 3 Original Placebo | 7.8 |
All cause-mortality through clinic reports and National Death Index search (NCT00038727)
Timeframe: Outcomes were assessed throughout follow-up from 1996 to 2022. National Death Index search conducted in 2019 using early release data as of Dec 2018.
| Intervention | Participants (Count of Participants) |
|---|---|
| 1 Original Lifestyle | 158 |
| 2 Original Metformin | 152 |
| 3 Original Placebo | 143 |
Aggregate microvascular disease is defined as the average prevalence of 3 components: (1) retinopathy measured by photography (ETDRS of 20 or greater); (2) neuropathy detected by Semmes Weinstein 10 gram monofilament, and (3) nephropathy based on estimated glomerular filtration rate (eGFR by chronic kidney disease (CKD-Epi) equation ) (<45 ml/min, confirmed) and albumin-to-creatinine ratio in spot urine (> 30mg/gm, confirmed). (NCT00038727)
Timeframe: Outcomes were assessed from 2012-2013 (approximately 2 years).
| Intervention | average percentage of participants (Number) |
|---|---|
| 1 Original Lifestyle | 11.3 |
| 2 Original Metformin | 13 |
| 3 Original Placebo | 12.4 |
Measured using coronary artery calcification (CAC). (NCT00038727)
Timeframe: Outcomes were assessed from 2012-2013 (approximately 2 years).
| Intervention | CAC geometric mean in AU (Geometric Mean) | |
|---|---|---|
| Men | Women | |
| 1 Original Lifestyle | 70.1 | 6.0 |
| 2 Original Metformin | 40.2 | 6.1 |
| 3 Original Placebo | 63.7 | 5.3 |
Change in percent body fat (NCT01881828)
Timeframe: 0-26 weeks
| Intervention | percentage of change (Mean) |
|---|---|
| Metformin | -0 |
| Oral Placebo | 1 |
(NCT01881828)
Timeframe: 0-26 weeks
| Intervention | percentile (Mean) |
|---|---|
| Metformin | -1 |
| Oral Placebo | 1 |
(NCT01881828)
Timeframe: 0-26 weeks
| Intervention | insulin per kg (Mean) |
|---|---|
| Metformin | -0.1 |
| Oral Placebo | -0.0 |
(NCT01881828)
Timeframe: 0-26 weeks
| Intervention | centimeters (Mean) |
|---|---|
| Metformin | -0 |
| Oral Placebo | 1 |
(NCT01881828)
Timeframe: 0-26 weeks
| Intervention | mm Hg (Mean) | |
|---|---|---|
| Change in Systolic | Change in Diastolic | |
| Metformin | 0 | 0 |
| Oral Placebo | -0 | 0 |
Hemoglobin A1c is a measure of glycemic control over approximately the past 3 months (NCT01881828)
Timeframe: 0-26 weeks
| Intervention | percentage (Mean) | |
|---|---|---|
| HbA1c | Change from Baseline to 26 Weeks | |
| Metformin | 9.0 | 0.2 |
| Oral Placebo | 8.9 | 0.2 |
Hemoglobin A1c is a measure of glycemic control over approximately the past 3 months (NCT01881828)
Timeframe: 0-26 weeks
| Intervention | percentage of participants (Number) | ||
|---|---|---|---|
| HbA1c Decrease ≥0.5% | HbA1c Increase ≥0.5% | HbA1c <7.5% | |
| Metformin | 19 | 44 | 3 |
| Oral Placebo | 18 | 35 | 4 |
(NCT01881828)
Timeframe: 0-26 weeks
| Intervention | mg/dL (Mean) | ||||
|---|---|---|---|---|---|
| Change in LDL | Change in VLDL | Change in HDL | Change in Triglycerides | Change in Total Cholesterol | |
| Metformin | -6 | -0 | -0 | 4 | -5 |
| Oral Placebo | 2 | 1 | -1 | 6 | 3 |
7 reviews available for metformin and Vascular Diseases
| Article | Year |
|---|---|
Repurposing Metformin for Vascular Disease.
Topics: Aging; Animals; COVID-19; Drug Repositioning; Endothelial Cells; Exercise; Humans; Metformin; Vascul | 2023 |
Vascular and metabolic effects of metformin added to insulin therapy in patients with type 1 diabetes: A systematic review and meta-analysis.
Topics: Diabetes Mellitus, Type 1; Drug Therapy, Combination; Humans; Hypoglycemic Agents; Insulin; Metformi | 2020 |
Metformin: An Old Drug for the Treatment of Diabetes but a New Drug for the Protection of the Endothelium.
Topics: Adenylyl Cyclases; AMP-Activated Protein Kinases; Diabetes Mellitus, Type 2; Dose-Response Relations | 2015 |
AMPK and vasculoprotection.
Topics: AMP-Activated Protein Kinases; Animals; Endothelium, Vascular; Humans; Hydroxymethylglutaryl-CoA Red | 2011 |
Microvascular diseases: is a new era coming?
Topics: Diabetic Angiopathies; Hemorheology; Humans; Metformin; Microcirculation; Microvessels; Myocardial I | 2012 |
Insulin and type 2 diabetes. Last resort or rational management?
Topics: Adult; Blood Glucose; Clinical Protocols; Diabetes Mellitus, Type 2; Drug Administration Schedule; D | 1999 |
The position of long-term stimulation of the endogenous fibrinolytic system: present achievements and clinical perspectives.
Topics: Adrenocorticotropic Hormone; Anabolic Agents; Androgens; Clofibrate; Coronary Disease; Deamino Argin | 1975 |
6 trials available for metformin and Vascular Diseases
| Article | Year |
|---|---|
Similar cardiovascular outcomes in patients with diabetes and established or high risk for coronary vascular disease treated with dulaglutide with and without baseline metformin.
Topics: Aged; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Female; Glucagon-Like Peptide-1 Receptor; | 2021 |
Long-term effects of lifestyle intervention or metformin on diabetes development and microvascular complications over 15-year follow-up: the Diabetes Prevention Program Outcomes Study.
Topics: Diabetes Mellitus, Type 2; Female; Follow-Up Studies; Humans; Hypoglycemic Agents; Life Style; Male; | 2015 |
Long-term effects of lifestyle intervention or metformin on diabetes development and microvascular complications over 15-year follow-up: the Diabetes Prevention Program Outcomes Study.
Topics: Diabetes Mellitus, Type 2; Female; Follow-Up Studies; Humans; Hypoglycemic Agents; Life Style; Male; | 2015 |
Long-term effects of lifestyle intervention or metformin on diabetes development and microvascular complications over 15-year follow-up: the Diabetes Prevention Program Outcomes Study.
Topics: Diabetes Mellitus, Type 2; Female; Follow-Up Studies; Humans; Hypoglycemic Agents; Life Style; Male; | 2015 |
Long-term effects of lifestyle intervention or metformin on diabetes development and microvascular complications over 15-year follow-up: the Diabetes Prevention Program Outcomes Study.
Topics: Diabetes Mellitus, Type 2; Female; Follow-Up Studies; Humans; Hypoglycemic Agents; Life Style; Male; | 2015 |
Evaluation of endothelial function in women with polycystic ovary syndrome.
Topics: Adolescent; Adult; Case-Control Studies; Endothelium, Vascular; Female; Follicular Phase; Humans; Hy | 2007 |
Evaluation of endothelial function in women with polycystic ovary syndrome.
Topics: Adolescent; Adult; Case-Control Studies; Endothelium, Vascular; Female; Follicular Phase; Humans; Hy | 2007 |
Evaluation of endothelial function in women with polycystic ovary syndrome.
Topics: Adolescent; Adult; Case-Control Studies; Endothelium, Vascular; Female; Follicular Phase; Humans; Hy | 2007 |
Evaluation of endothelial function in women with polycystic ovary syndrome.
Topics: Adolescent; Adult; Case-Control Studies; Endothelium, Vascular; Female; Follicular Phase; Humans; Hy | 2007 |
Treatment with low dose metformin in patients with peripheral vascular disease.
Topics: Aged; Exercise Test; Humans; Lipids; Lipoproteins; Male; Metformin; Middle Aged; Plethysmography; Va | 1992 |
Fibrinolytic effects of diguanides plus ethyloestrenol in occlusive vascular disease.
Topics: Adult; Aged; Angina Pectoris; Biguanides; Blood Coagulation Tests; Cholesterol; Ethylestrenol; Femal | 1967 |
HB419 (glibenclamide) in the treatment of diabetes mellitus.
Topics: Adult; Age Factors; Aged; Biguanides; Chlorpropamide; Clinical Trials as Topic; Diabetes Complicatio | 1969 |
9 other studies available for metformin and Vascular Diseases
| Article | Year |
|---|---|
Quercetin and metformin synergistically reverse endothelial dysfunction in the isolated aorta of streptozotocin-nicotinamide- induced diabetic rats.
Topics: Animals; Diabetes Mellitus, Experimental; Endothelium, Vascular; Hypoglycemic Agents; Metformin; Nia | 2022 |
Quercetin and metformin synergistically reverse endothelial dysfunction in the isolated aorta of streptozotocin-nicotinamide- induced diabetic rats.
Topics: Animals; Diabetes Mellitus, Experimental; Endothelium, Vascular; Hypoglycemic Agents; Metformin; Nia | 2022 |
Quercetin and metformin synergistically reverse endothelial dysfunction in the isolated aorta of streptozotocin-nicotinamide- induced diabetic rats.
Topics: Animals; Diabetes Mellitus, Experimental; Endothelium, Vascular; Hypoglycemic Agents; Metformin; Nia | 2022 |
Quercetin and metformin synergistically reverse endothelial dysfunction in the isolated aorta of streptozotocin-nicotinamide- induced diabetic rats.
Topics: Animals; Diabetes Mellitus, Experimental; Endothelium, Vascular; Hypoglycemic Agents; Metformin; Nia | 2022 |
Empagliflozin Improves the MicroRNA Signature of Endothelial Dysfunction in Patients with Heart Failure with Preserved Ejection Fraction and Diabetes.
Topics: Aged; Biomarkers; Diabetes Mellitus; Heart Failure; Humans; Insulins; Metformin; MicroRNAs; Sodium-G | 2023 |
Metformin alleviates monoamine oxidase-related vascular oxidative stress and endothelial dysfunction in rats with diet-induced obesity.
Topics: Animals; Aorta; Disease Models, Animal; Endothelium, Vascular; Hypoglycemic Agents; Male; Metformin; | 2021 |
Metformin ameliorates ovariectomy-induced vascular dysfunction in non-diabetic Wistar rats.
Topics: Acetylcholine; Animals; Endothelium, Vascular; Female; Hypoglycemic Agents; Membrane Glycoproteins; | 2014 |
Prevention of diabetes: more answers, more questions.
Topics: Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Life Style; Male; Metformin; Vascula | 2015 |
Increased Risk of Herpes Zoster in Diabetic Patients Comorbid with Coronary Artery Disease and Microvascular Disorders: A Population-Based Study in Taiwan.
Topics: Adolescent; Adult; Aged; Case-Control Studies; Comorbidity; Coronary Artery Disease; Databases, Fact | 2016 |
Changes in albumin excretion in the diabetes prevention program.
Topics: Adult; Aged; Albuminuria; Creatinine; Diabetes Mellitus; Diabetic Nephropathies; Female; Humans; Hyp | 2009 |
A summary of the ADVANCE Trial.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic Retinopathy; Disease Progr | 2009 |
Effect of ethyloestrenol combined with phenformin or with metformin on platelet stickiness and serum-cholesterol in patients with occlusive vascular disease.
Topics: Aged; Anticholesteremic Agents; Blood Coagulation Tests; Blood Platelets; Butyrates; Cholesterol; Co | 1968 |